NTRA250516P220000
- 0.00
- 0.000.00%
Natera Newsroom
Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $185
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Natera (NTRA) and Regeneron (REGN)
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $200 to $251
Natera Inc. Shines in Earnings Call With Strong Growth
Express News | UBS Maintains Buy on Natera, Raises Price Target to $218
Natera | 10-Q: Q1 2025 Earnings Report
Natera (NTRA) Receives a Buy From Piper Sandler
Natera Is Maintained at Overweight by Barclays
8 Analysts Have This To Say About Natera
Natera Analyst Ratings
Barclays Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $190
Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating
Express News | Natera Inc : Btig Raises Target Price to $195 From $190
NATERA Earnings Results: $NTRA Reports Quarterly Earnings
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
Natera Q1 Net Loss Narrows, Revenue Rises; Increases Full Year Revenue Outlook
Natera: Q1 Earnings Snapshot
Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.
Earnings Flash (NTRA) NATERA INC. Reports Q1 Revenue $501.8M, Vs. FactSet Est of $446.2M